The Immu-KNEE-ty Study
The Effect of Total Knee Replacement Surgery on Immune Functioning in Elderly
1 other identifier
observational
14
1 country
1
Brief Summary
The goal of this observational study is to determine changes in immune functioning after total knee replacement surgery in elderly. The study population consists of 14 patients aged 65 years or over undergoing primary total knee replacement surgery. Immune functioning will be assessed at multiple timepoints before and after surgery (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery). Each patient will serve as his/her own control. Immune functioning will primarily be assessed by determining the change from baseline in monocyte-derived TNFα production at 1 week after surgery. Changes in monocyte responsiveness are considered indicative for changes in immune functioning. As secondary objective, additional parameters of immune functioning will be assessed. In addition, the course of immune functioning following total knee replacement surgery will be investigated. Burden and potential risks for the patient are estimated to be minor. During the study, 5 blood samples of 20 mL will be collected over a period of ± 12 weeks, resulting in a total blood draw of 100 mL. During surgery a sample of synovial fluid (± 2 mL) will be taken from surgical waste. Before and after surgery patients will report their pain medication intake and the presence of cold and flu-like symptoms in a diary. Patients do not directly benefit from the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2023
CompletedFirst Posted
Study publicly available on registry
June 27, 2023
CompletedStudy Start
First participant enrolled
March 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 11, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 11, 2024
CompletedMarch 4, 2025
June 1, 2024
9 months
June 15, 2023
February 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Monocyte-derived TNFa production
TNFα production after ex vivo stimulation of whole blood with inflammatory stimuli corrected for monocyte count
Change from baseline at 1 week after surgery
Secondary Outcomes (30)
Monocyte-derived cytokine production
Change from baseline at 1 day after surgery
Monocyte-derived cytokine production
Change from baseline at 1 week after surgery
Monocyte-derived cytokine production
Change from baseline at ± 2 weeks after surgery
Monocyte-derived cytokine production
Change from baseline at ± 6 weeks after surgery
Monocyte-derived cytokine production
Change from baseline at 1 day after surgery
- +25 more secondary outcomes
Other Outcomes (16)
Body Mass Index
Baseline
American Society of Anesthesiologists (ASA) classification
Baseline
Kellgren-Lawrence classification
Baseline
- +13 more other outcomes
Study Arms (1)
Elderly
Interventions
At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
Eligibility Criteria
The study population consists of 14 patients (classified as ASA II or ASA III) aged 65 years or over, diagnosed with osteoarthritis, undergoing primary total knee replacement surgery.
You may qualify if:
- Planned for primary total knee replacement surgery
- Aged 65 years or over
- Diagnosed with osteoarthritis
- ASA Physical Status Classification of II or III
- Willing to donate a blood sample at 5 different timepoints
- Able to give written informed consent
You may not qualify if:
- Use of systemic corticosteroids
- Current diagnosis of cancer
- Diagnosed with a primary immunodeficiency disorder (e.g., Severe Combined Immunodeficiency (SCID), Common Variable Immune Deficiency (CVID), X-linked agammaglobulinemia, selective immunoglobulin A deficiency, chronic granulomatous disease)
- Current participation in other scientific research
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wageningen Universitylead
- Wageningen University and Researchcollaborator
- Gelderse Vallei Hospitalcollaborator
Study Sites (1)
Gelderse Vallei Hospital
Ede, 6716 RP, Netherlands
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator / Associate Professor
Study Record Dates
First Submitted
June 15, 2023
First Posted
June 27, 2023
Study Start
March 12, 2024
Primary Completion
December 11, 2024
Study Completion
December 11, 2024
Last Updated
March 4, 2025
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will not share